Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden

References

• Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22:848–9.
   PubMedGoogle Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Hankin CS, Bronstone A, Wang Z, et al. Estimated prevalence and economic burden of severe, uncontrolled asthma in the USA. J Allergy Clin Immunol. 2013;131:AB126.
   Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896–902.
   PubMed Web of Science ®Google Scholar
• GBD. DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2016;390(2017): 1260–1344.
   Google Scholar
• GBD. Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2016;390(2017): 1211–1259.
   Google Scholar
• Omachi TA, Iribarren C, Sarkar U, et al ., Risk factors for death in adults with severe asthma. Ann Allergy Asthma Immunol. 2008;101:130–136.
   PubMed Web of Science ®Google Scholar
• Suruki RY, Daugherty JB, Boudiaf N, et al. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17:74.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Dalal AA, et al, Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016;4:120–129 e123.
   PubMed Web of Science ®Google Scholar
• Honkamaki J, Hisinger-Molkanen H, Ilmarinen P, et al. Age- and gender-specific incidence of new asthma diagnosis from childhood to late adulthood. Respir Med. 2019;154:56–62.
   PubMed Web of Science ®Google Scholar
• Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–1222.
   PubMed Web of Science ®Google Scholar
• Larsson K, Ställberg B, Lisspers K, et al. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respir Res. 2018;19:12.
   PubMed Web of Science ®Google Scholar
• Viinanen A, Lassenius MI, Toppila I, et al. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization. J Asthma. 2020;57:1092–1102.
   PubMed Web of Science ®Google Scholar
• von Bülow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2:759–767.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2020, <https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf&#x003E
   Google Scholar
• Jansson SA, Backman H, Andersson M, et al. Severe asthma is related to high societal costs and decreased health related quality of life. Respir Med. 2020;162:105860.
   PubMed Web of Science ®Google Scholar
• Janson C, Lisspers K, Stallberg B, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). Respir Res. 2018;19:168.
   PubMed Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276–293.
   PubMed Web of Science ®Google Scholar
• Volmer T, Effenberger T, Trautner C, et al. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52:1800703.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH. et al, Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136:1488–1495.
   PubMed Web of Science ®Google Scholar
• Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19:75.
   PubMed Web of Science ®Google Scholar
• Ekstrom M, Nwaru BI, Hasvold P, et al. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74:2181–2190.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Rogers L, Peters JI. Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use. Ther Clin Risk Manag. 2018;14:2059–2068.
   PubMed Web of Science ®Google Scholar
• Leung E, Al Efraij K, FitzGerald JM. The safety of mepolizumab for the treatment of asthma. Expert Opin Drug Saf. 2017;16:397–404.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Shaw D, Menzies-Gow A, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2019;1–9. DOI:10.1080/02770903.2019.1705333.
   Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bel EH, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE trial. ERJ Open Res. 2019;5. DOI:10.1183/23120541.00009-2019.
   Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2020. DOI:10.1016/j.chest.2020.08.2083.
   Web of Science ®Google Scholar
• Menzies-Gow A, Haslam T, Morris T, et al. P144  regional variation in OCS use for UK patients with asthma: heat map analysis. Thorax. 2019;74:A169–A169.
   Web of Science ®Google Scholar
• Chapman KR, Remtulla A, Gendron A, et al. Regional variation in asthma prevalence and oral corticosteroid use for Canadian patients: heat map analysis. Am J Respir Crit Care Med. 2020;201:A1835–A1835.
   Web of Science ®Google Scholar
• Tran TN, King E, Sarkar R, et al, Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK. Eur Respir J. 2020;55. DOI:10.1183/13993003.02363-2019.
   Web of Science ®Google Scholar
• Bleecker ER, Gandhi H, Gilbert I, et al. Mapping geographic variability of severe uncontrolled asthma in the USA: management implications. Ann Allergy Asthma Immunol. 2022;128:78–88.
   Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, <http://www.ginasthma.org&#x003E; (2018).
   Google Scholar
• Hew M, McDonald VM, Bardin PG, et al. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust. 2020;213:316–320.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Beckert L, Moran A, et al, Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia. Respirology. 2017;22:1570–1578.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Barnes PJ, Chipps BE, et al, The burden of exacerbations in mild asthma: a systematic review. ERJ Open Res. 2020;6:00359–02019.
   Google Scholar